Onxeo S.A., an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent application has been filed in the US and Europe and will be expanded to include other regions, including the Asian territories, under the patent review procedure. If granted, this patent would protect Livatag® until 2036.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.
Transparency Market Research (TMR) has recently published a market study based on the global nanomedicine market, estimating the market to grow at a healthy CAGR of 12.3% during the period from 2013 to 2019 in order to reach US$177.60 billion by 2019.The study, titled "Nanomedicine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", reports that the global nanomedicine market stood at US$78.54 billion in 2012.
Dr. Ronald J. Tackett, faculty member in the Kettering University department of Physics, along with collaborators from multiple disciplines across campus have been awarded a National Science Foundation - Major Research Instrumentation (NSF-MRI) grant for $452,000. The grant will allow Tackett to acquire a high-resolution transmission electron microscope (TEM) with energy dispersive spectroscopy capabilities to support ongoing investigations and potentially advance materials science and nanotechnology research and teaching at Kettering.
CeloNova BioSciences, Inc. (CN) has announced that it enrolled the first patient in its multicenter e-COBRA clinical study in France. This prospective registry will further assess the safety and efficacy of the novel COBRA PzF coronary stent system in real world and complex patients with heart disease.
NantPharma, LLC, a subsidiary of NantWorks, LLC, having recently acquired the pharmaceutical product nant-paclitaxel (formerly Cynviloq), today announced that it has entered into an exclusive license agreement with Amgen Inc. for AMG 337. Under the agreement, NantPharma acquired the exclusive rights to develop and commercialize worldwide, excluding Japan, Russia and certain other Central Asian countries, AMG 337, a phase 2 small molecule inhibitor of the cell surface enzyme c-Met, an important target for cancer therapy.
A US-Ireland partnership involving researchers at Queen’s University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.
As a potential treatment for Parkinson's disease, scientists at the University of North Carolina at Chapel Hill have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves.
Rutgers engineers have developed a breakthrough device that can significantly reduce the cost of sophisticated lab tests for medical disorders and diseases, such as HIV, Lyme disease and syphilis.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was awarded a $1.7 million grant by the National Cancer Institute for clinical testing of a new technology called Theranostics, which is an integration of early diagnosis and treatment of melanoma.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.